Torisel Review Uncovers Protocol Violations That Extended PDUFA Date
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Wyeth’s failure to follow protocol-defined RECIST criteria for measuring tumor response in the pivotal trial for its renal cell carcinoma therapy Torisel was the reason that the drug’s user fee date was extended, according to FDA review documents.
You may also be interested in...
Asia Spotlight: Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.
Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China: An Interview With PharmAsia News (Part 2 of 2)
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.
Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China: An Interview With PharmAsia News (Part 1 of 2)
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: